These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 34715057

  • 1. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 2. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 3. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 4. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 25; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 6. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 25; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 25; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 8. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 25; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L, He M, Wang W, Li S, Zhao G.
    Eur J Pediatr; 2024 Apr 25; 183(4):1765-1776. PubMed ID: 38240765
    [Abstract] [Full Text] [Related]

  • 10. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
    Jaggi P, Wang W, Dvorchik I, Printz B, Berry E, Kovalchin JP, Texter K, Ramilo O, Burns JC, Tremoulet AH.
    Pediatr Infect Dis J; 2015 Dec 25; 34(12):1315-8. PubMed ID: 26353031
    [Abstract] [Full Text] [Related]

  • 11. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 12. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S, Seki M, Minami T, Kotani K, Oka K, Yokomizo A, Matsubara D, Sato T, Nozaki Y, Saito M, Kikuchi Y, Miyamoto K, Monden Y, Yamagata T.
    Pediatr Rheumatol Online J; 2021 Jul 03; 19(1):107. PubMed ID: 34217297
    [Abstract] [Full Text] [Related]

  • 14. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 03; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
    Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
    [Abstract] [Full Text] [Related]

  • 16. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 17. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 18. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 19. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J, Jain S, Capparelli EV, Best BM, Son MB, Baker A, Newburger JW, Franco A, Printz BF, He F, Shimizu C, Hoshino S, Bainto E, Moreno E, Pancheri J, Burns JC, Tremoulet AH.
    J Pediatr; 2022 Apr 11; 243():173-180.e8. PubMed ID: 34953816
    [Abstract] [Full Text] [Related]

  • 20. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
    Xue LJ, Wu R, Du GL, Xu Y, Yuan KY, Feng ZC, Pan YL, Hu GY.
    Clin Rev Allergy Immunol; 2017 Jun 11; 52(3):389-400. PubMed ID: 27550227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.